Gyno-Pevaryl Cream
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Gyno-Pevaryl Cream.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 100 g of cream contains 1 g econazole nitrate (1% w/w).
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Vaginal cream
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the treatment of mycotic vulvovaginitis and mycotic balanitis.
4.2 Posology and method of administration
Route of Administration
For vaginal/penile administration.
Females: One applicator full (approximately 5 g) intravaginally once daily at night for not less than 14 days. The cream should also be applied to the vulva. The full 14 days treatment should be carried out even if the symptoms of vaginal itching or discharge have disappeared.
In pregnant women, it is recommended that administration takes place without the use of an applicator, or is performed by a physician. Pregnant women should thoroughly wash their hands before self-administering Gyno-Pevaryl cream.
Males: Apply the cream to the penis, including under the foreskin, once daily for not less than 14 days.
The sexual partner should also be treated.
4.3 Contraindications
Hypersensitivity to any imidazole preparation, other vaginal antifungal products or to any ingredients of Gyno- Pevaryl Cream.
4.4 Special warnings and precautions for use
Not for ophthalmic or oral use.
Hypersensitivity has rarely been recorded; if it should occur administration should be discontinued.
Contact between contraceptive diaphragms or condoms and this product must be avoided since the rubber may be damaged by the preparation.
Patients using spermicidal contraceptives should consult their physician since any local vaginal treatment may inactivate the spermicidal contraceptive (see section 4.5).
Gyno-Pevaryl Cream should not be used in conjunction with other internal or external treatment of the genitalia
Gyno-Pevaryl Cream is not indicated for use in children under the age of 16 years.
4.5 Interaction with other medicinal products and other forms of interaction
Econazole is a known inhibitor of CYP3A4/2C9. Due to the limited systemic availability after vaginal application (see Section 5.2. Pharmacokinetic Properties), clinically relevant interactions are unlikely to occur but have been reported with oral anticoagulants. In patients taking oral anticoagulants, such as warfarin or acenocoumarol, caution should be exercised and the anticoagulant effect should be monitored more frequently.
Adjustment of the oral anticoagulant dosage may be necessary during and after the treatment with econazole.
Contact between latex products such as contraceptive diaphragms or condoms and this product must be avoided since the constituents of the product may damage the latex. Patients using spermicidal contraceptives should consult their physician since any local vaginal treatment may inactivate the spermicidal contraceptive (see section 4.4).
4.6 Fertility, pregnancy and lactation Pregnancy
In animals, econazole nitrate has shown no teratogenic effects but is foetotoxic at high doses. The significance of this to man is unknown as there is no evidence of an increased risk when taken in human pregnancy. However, animal studies have shown reproductive toxicity (see section 5.3). Because
there is vaginal absorption, as with other imidazoles, econazole should be used in pregnancy only if the practitioner considers it to be necessary.
Breast-feeding
Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups. It is not known whether econazole nitrate is excreted in human milk. Caution should be exercised when using Gyno-Pevaryl Cream if the patient is breastfeeding.
Fertility
Results of econazole animal reproduction studies showed no effects on fertility.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
The safety of Gyno-Pevaryl Vaginal Cream and Vaginal Pessaries was evaluated in 3630 patients who participated in 32 clinical trials.
Based on pooled safety data from these clinical trials, the most commonly reported adverse reactions were (with % incidence) pruritus (1.2%) and skin burning sensation (1.2%).
Including the above mentioned adverse reactions, the following table displays adverse reactions that have been reported with the use of Gyno-Pevaryl Vaginal Cream and Vaginal Pessaries from either clinical trial or postmarketing experiences. The displayed frequency categories use the following convention:
Very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); very rare (<1/10,000); and not known (cannot be estimated from the available clinical trial data).
Adverse Reactions
|
System Organ Class |
Adverse Reactions | |||
|
Frequency Category | ||||
|
Common (>1/100 to <1/10) |
Uncommon (>1/1,000 to <1/100) |
Rare (>1/10,000 to <1/1,000) |
Not known | |
|
Immune System Disorders |
Hypersensitivity | |||
|
Skin and Subcutaneous Tissue Disorders |
Pruritus, Skin burning sensation |
Rash |
Erythema |
Angioedema, Urticaria, Contact dermatitis, Skin exfoliation |
|
System Organ Class |
Adverse Reactions | |||
|
Frequency Category | ||||
|
Common (>1/100 to <1/10) |
Uncommon (>1/1,000 to <1/100) |
Rare (>1/10,000 to <1/1,000) |
Not known | |
|
Reproductive System and Breast Disorders |
Vulvovaginal burning sensation | |||
|
General Disorders and Administrati on Site Conditions |
Application site pain, Application site irritation, Application site swelling | |||
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Adverse events associated with overdose or misuse of Gyno-Pevaryl Cream are expected to be consistent with adverse drug reactions already listed in Section 4.8. (Undesirable effects)
In the event of accidental ingestion, nausea, vomiting and diarrhoea may occur. If necessary treat symptomatically.
If the product is accidentally applied to the eyes, wash with clean water or saline and seek medical attention if symptoms persist.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic propertie s
Pharmacotherapeutic classification: (Antiinfectives and antiseptics, excl. combinations with corticosteroids, imidazole derivatives)
ATC code: G01A F05
Econazole nitrate has no anti-inflammatory action, no effect on circulation, no central or autonomic nervous effects, no effects on respiration, no effect on a or P receptors, no anticholinergic or antiserotonergic reactions.
A broad spectrum of antimycotic activity has been demonstrated against dermatophytes, yeasts and moulds. A clinically relevant action against Gram positive bacteria has also been found.
Econazole acts by damaging fungal cell membranes. The permeability of the fungal cell is increased. Sub-cellular membranes in the cytoplasm are damaged. The site of action is most probably the unsaturated fatty acid acyl moiety of membrane phospholipids.
5.2 Pharmacokinetic properties
Econazole nitrate is poorly absorbed from the vagina and skin. If given orally, peak plasma levels occur six hours after dosing. About 90% of the absorbed dose is bound to plasma proteins. Metabolism is limited, but primarily occurs in the liver, the metabolites excreted in the urine.
Five major and two minor metabolites have been identified.
5.3 Preclinical safety data
Low neonatal survival and foetal toxicity was associated with high doses. In animal studies, econazole nitrate has shown no teratogenic effects but was foetotoxic in rodents at maternal subcutaneous doses of 20 mg/kg/day and at maternal oral doses of 10 mg/kg/day. The significance of this in humans is unknown. In repeat dose toxicity studies in rats, at high subcutaneous doses (50 mg/kg/day, 300 mg/m7day) the liver was identified as a target organ with minimal toxicity and full recovery. The human to animal safety margin for liver toxicity (based on Human Equivalent Dose taking into account normalisation of body surface area) is 32 to 126x for a 50 to 70 kg human based on 2.5 to 7% absorption in humans and 83% bioavailability in rats. No significant topical toxicity, phototoxicity, local dermal irritation, vaginal irritation or sensitization was noted. Only mild ocular irritation was noted with a cream formulation.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Tefose 63
Labrafil M 1944 CS Mineral oil
Butylated hydroxyanisole (E320) Benzoic acid (E210)
Purified water
6.2 Incompatibilities
None stated
6.3 Shelf life
24 months
6.4 Special precautions for storage
Do not store above 25°C.
6.5 Nature and contents of container
Aluminium lacquered tubes Pack sizes: 78g, 30g, 15g
6.6 Special precautions for disposal
None stated.
7 MARKETING AUTHORISATION HOLDER
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe
Buckinghamshire HP12 4EG UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 00242/0229
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 09/08/1978 Date of renewal: 17/06/2003
10
DATE OF REVISION OF THE TEXT
29/07/2016